tirzepatide hepatic impairment child-pugh score of liver diseases tirzepatide hepatic impairment child-pugh Rating

Studies on pregnant animals showed some concerning results: Smaller baby sizes Birth defects in bones and organs Higher rates of miscarriage Problems with baby growth The FDA puts semaglutide and tirzepatide in pregnancy category C. This means we cant rule out risks to a developing baby

The medication works by mimicking incretin hormones that regulate blood glucose and appetite

It requires the largest injection volumes, which makes it ideal for lower doses where precision matters but becomes impractical at higher doses

Instead of increasing every 4 weeks as the standard protocol suggests, staying at each dose for 6 to 8 weeks can reduce the severity of heartburn during transitions